A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model-Reference-Cited by-同舟云学术

A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model

Published:2017-01 Issue:1 Volume:133 Page:25-33
ISSN:1347-8613
Container-title:Journal of Pharmacological Sciences
language:en
Short-container-title:Journal of Pharmacological Sciences

Author:

Ito Misato,Yamazaki Shunji,Yamagami Kaoru,Kuno Masako,Morita Yoshiaki,Okuma Kenji,Nakamura Koji,Chida Noboru,Inami Masamichi,Inoue Takayuki,Shirakami Shohei,Higashi Yasuyuki

Publisher

Elsevier BV

Subject

Pharmacology,Molecular Medicine

Reference26 articles.

1. The Jak-STAT pathway;Imada;Mol Immunol,2000

2. Cytokine receptor signaling pathways;Leonard;J Allergy Clin Immunol,2000

3. FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis;Sakuma;Inflamm Res,2001

4. Janus kinases in immune cell signaling;Ghoreschi;Immunol Rev,2009

5. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders;Benson;MAbs,2011

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and molecular docking of novel 4-morpholino-1H-pyrrolo[2,3-b] pyridine-5-carboxamides and 4-methylpiperazin-1H-pyrrolo[2,3-b] pyridine-5-carboxamides for the evaluation anti-cancer activity;Journal of Molecular Structure;2024-09

2. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis;PLOS ONE;2024-06-21

3. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma;Science;2024-06-21

4. FDA-Approved Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) Inhibitors for Managing Rheumatoid Arthritis: A Narrative Review of the Literature;Cureus;2024-05-09

5. Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies;Molecular Cancer;2024-04-05